When patients are given the choice between a take-home test kit or undergoing a colonoscopy, more patients voluntarily undergo screenings, according to a May 22 press release from Penn Medicine.
The study looked at 738 patients aged 50-74 at a community health center in Pottstown, Pa., where about half of the patients are receiving Medicaid. The baseline colorectal cancer screening rate before the trial was about 22%, much lower than the national average of 72%.
“Offering the choice of colonoscopy or take-home kits seem to have the advantage of maximizing the rates of colonoscopy—the most effective screening tool—while not overloading individuals with too much of a choice, which could have lowered overall participation,” Shivan Mehta, MD, Penn Medicine’s associate chief innovation officer, associate professor of gastroenterology and the study’s lead author, said in the release.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
